Context Therapeutics Partners With Integral Molecular To Develop An Emerging Cancer Drug
November 10, 2022 at 08:13 AM EST
Context Therapeutics Inc. (NASDAQ: CNTX) and Integral Molecular are teaming up to develop an anti-claudin 6 (CLDN6) bispecific ...